INmune Bio
INMB
INMB
33 hedge funds and large institutions have $10.2M invested in INmune Bio in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.49% less ownership
Funds ownership: 10.66% → 9.17% (-1.5%)
12% less capital invested
Capital invested by funds: $11.7M → $10.2M (-$1.43M)
Holders
33
Holding in Top 10
–
Calls
$443K
Puts
$167K
Top Buyers
| 1 | +$184K | |
| 2 | +$101K | |
| 3 | +$86.5K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$32.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.5K |
Top Sellers
| 1 | -$799K | |
| 2 | -$221K | |
| 3 | -$66.5K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$60.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$32.2K |